Neoplasms by Histologic Type  >>  Gazyva (obinutuzumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
NCT01998880: CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)

Completed
3
787
Canada, US, Europe, RoW
obinutuzumab, RO5072759, GA101, GAZYVA®, rituximab, Rituxan®, MabThera®, chlorambucil
Hoffmann-La Roche, German CLL Study Group, Genentech, Inc.
Lymphocytic Leukemia, Chronic
08/12
08/17
NCT02053610: CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)

Completed
3
787
Canada, US, Europe, RoW
obinutuzumab, RO5072759, GA101, GAZYVA®, Gazyvaro, rituximab, Rituxan®, MabThera®, chlorambucil
Hoffmann-La Roche, German CLL Study Group, Genentech, Inc.
Lymphocytic Leukemia, Chronic
08/13
08/17

Download Options